This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The siRNA targeted to mdr1b and mdr1a mRNAs in vivosensitizes murine lymphosarcoma to chemotherapy
BMC Cancer Open Access 14 May 2010
-
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Molecular Cancer Open Access 12 April 2010
-
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
British Journal of Cancer Open Access 06 May 2008
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697–704.
Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE . hOCT1 and resistance to imatinib. Blood 2005; 106: 1133–1134, author reply 1134.
Rumpold H, Wolf AM, Wolf D . The role of P-glycoporotein in imatinib resistance. Leukemia 2006; 20: 144 author reply 144-145.
Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070–1079.
Ferrao PT, Frost MJ, Siah SP, Ashman LK . Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 2003; 102: 4499–4503.
Zong Y, Zhou S, Sorrentino BP . Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia 2005; 19: 1590–1596.
Rumpold H, Wolf AM, Gruenewald K, Gastl G, Gunsilius E, Wolf D . RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol 2005; 33: 767–775.
Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A et al. Population Pharmacokinetics of imatinib and role of alpha-1-acid glycoprotein. Br J Clin Pharmacol 2006; 62: 97–112.
Acknowledgements
Alexandre Béguin, Laboratory of Clinical Pharmacology, University Hospital, Lausanne, is acknowledged for excellent technical support. Imatinib mesylate and imatinib-d8 were kindly provided by Novartis Pharma (Basel, Switzerland).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Widmer, N., Rumpold, H., Untergasser, G. et al. Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia 21, 1561–1562 (2007). https://doi.org/10.1038/sj.leu.2404671
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404671
This article is cited by
-
ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors
Pharmaceutical Research (2014)
-
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
Leukemia (2011)
-
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Molecular Cancer (2010)
-
The siRNA targeted to mdr1b and mdr1a mRNAs in vivosensitizes murine lymphosarcoma to chemotherapy
BMC Cancer (2010)
-
Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2
Leukemia (2008)